Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Age-related memory decline and neurodegenerative diseases like Alzheimer's are often thought of as irreversible. But the brain is not static; neurons continually adjust the strength of their ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

As an innovative subtype of invasive brain-computer interfaces (BCIs), the Endovascular Brain-Computer Interface (EBCI) enables electrode delivery to target brain regions via endovascular intervention ...

Age-related memory decline and neurodegenerative diseases like Alzheimer's are often thought of as irreversible. But the ...

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and memory impairment ...

Age-related memory decline and neurodegenerative diseases like Alzheimer's are often thought of as irreversible.

This study presents a bio-inspired control framework for soft robots, enhancing tracking accuracy by over 44% under disturbances while maintaining stability.

Synaptics enters 2026 with a problem it can live with. Many people still picture it as the company behind your laptop’s touchpad. That legacy is real, and it paid the bills for a long time. But it ...

In this article, we explain how to use CCleaner to reduce the startup time of your Windows computer and which programs you ...

Synaptics (SYNA) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $0.92 per share a year ago. These figures ...